6 known cases. View patent page →
Arbutus and Genevant sued Moderna over the Moderna COVID-19 vaccine, originally asserting six patents including US 8,822,668. The '668 patent was dropped during bilateral narrowing before trial. The case settled globally on March 3, 2026, with Moderna consenting to judgment on the four surviving patents, and Moderna later appealed.
Moderna's appeal from the District of Delaware action, primarily raising its 28 U.S.C. § 1498 government-contractor immunity defense. US 8,822,668 is tagged to the appeal via the underlying docket, but the appeal concerns the four patents actually adjudicated.
Arbutus and Genevant sued Moderna and ModernaTX in D. Del. asserting six LNP patents, including 11141378. The case settled March 3, 2026 as part of a $2.25 billion global settlement; Moderna consented to a judgment of infringement and no invalidity on four asserted patents, and the docket terminated March 4, 2026.
Reported but unconfirmed D.N.J. declaratory-judgment action by Acuitas against Arbutus and Genevant, challenging a list of patents including 11141378 and other Arbutus family patents. The narrative could not independently verify the case number 3:23-cv-04200 against the Acuitas caption.
Inter partes review of US 9,364,435. The PTAB confirmed claims 7-8, 10-11, 13 and 16-20, but held claims 1-6, 9, 12 and 14-15 unpatentable as anticipated, leaving the '435 patent with a subset of claims.
Earlier New York declaratory judgment action by Acuitas against Genevant (et al.) listed on the '435 patent's litigation linkage. It was withdrawn/not pursued in New York, and Acuitas refiled the declaratory judgment action in New Jersey (3:23-cv-04200).